ShortBusters Club's Dirks Issues Buy Recommendation on

Hemispherx - Projects $1.60 EPS for Just 1% Global Market Penetration for CFS New York (ots-PRNewswire) - Ray Dirks, founder of the ShortBusters Club, has issued a buy recommendation on Hemispherx Biopharma, Inc. (Amex: HEB), based on important progress in the Company's development of a new class of drugs for the treatment of chronic viral disorders and disorders of the immune system. Mr. Dirks, whose comments appear in the January/February issue of Equities magazine that was just released, states that Ampligen, which is in Phase III clinical testing for the treatment of Chronic Fatigue Syndrome (CFS), would have a seven- year legal monopoly in the U.S. if approved because of the Orphan Drug status it has been accorded by the FDA and has an application pending with the FDA for fast track approval. The Company has already submitted an application for marketing the drug in the European Union. In the article, Mr. Dirks states that his health-care industry analysts project that Hemispherx would realize pre-tax earnings of approximately $40 million, or $1.60 net earnings per share, by penetrating just 1% of the potential global market for CFS. Overall, according to the article, Hemispherx could be within two years of marketing its lead drug for the treatment of CFS and longer-term has the potential for application in the treatment of additional chronic viral diseases, including HIV and Hepatitis B. ShortBusters Club, founded in 1990 by Ray Dirks, disseminates research on fundamental strengths and growth prospects of companies whose stocks are under attack by abusive short sellers. Ray Dirks is with Security Capital Trading, a member of the National Association of Securities Dealers, CRD number 35909. ots Original Text Service: ShortBusters Club Internet: Contact: Ray Dirks of ShortBusters Club (USA) 212-339-2001.

Klíčová slova

Praha, Česká republika (ce)


Přihlásit k odběru

Materiály označené značkou Protext nejsou součástí zpravodajského servisu ČTK a nelze je publikovat pod její značkou. Jde o komerční sdělení zadavatele, který je ve zprávě označen a který za ně nese plnou odpovědnost.